Recent
Major studies link finasteride, a popular hair-loss drug, to depression, anxiety, and suicide, spurring criticism of Merck and FDA for delayed action. Experts call for urgent drug safety reforms.
October 13, 2025
Source:
ScienceDaily
Major Studies Link Finasteride to Psychiatric Harm
Large-scale research shows a significant connection between finasteride (commonly prescribed for hair loss) and increased risk of depression, anxiety, and suicidal thoughts. Eight international studies since 2017, drawing data from adverse event registries and healthcare records, reveal:
Fivefold increase in reporting odds for suicidal ideation among users (Psychiatrist.com).
Hazard ratios near 2 for depression and self-harm, even after accounting for mental health history (PubMed).
4 million users globally, possibly leading to hundreds of thousands of new depression cases and up to thousands of suicides (ScienceDaily).
Scientific Mechanism and Symptoms
Finasteride blocks neurosteroid synthesis, which is critical for mood and stress regulation. Disruption here is strongly linked to psychiatric symptoms. Many affected users report persistent symptoms even after stopping the medication—a scenario referred to as post-finasteride syndrome.
Keep up with the story. Subscribe to the PR+ free daily newsletter
Source:
SciTechDaily
Regulatory and Industry Response Under Fire
Concerns about finasteride's psychiatric risks arose as early as 2002, but regulatory measures were slow to follow. The FDA only added depression as a potential side effect in 2011, and suicidal thoughts in 2022, despite mounting evidence (ScienceDaily). European regulators (EMA) recognized the risks, now requiring warnings and patient information cards (EMA), though the drug remains on the market.
Manufacturer and FDA Criticized
Merck, the manufacturer, is criticized for failing to conduct or publish required post-marketing safety analyses (Healthline).
The FDA has been called out for lack of independent review and transparency, with some internal files heavily redacted and marked "confidential."
Experts now urge real-time monitoring and accountability for all drugs, particularly those meant for cosmetic concerns.
Read More
Source:
The Canadian Friends of Hebrew University
Calls for Reform and Practical Guidance
Researchers and clinicians advocate urgent reforms. They emphasize the need for transparent, mandatory post-marketing surveillance—especially for cosmetic medications with broad use. Regulatory bodies and manufacturers face pressure to:
Enhance labeling and patient warnings immediately (Healthline).
Monitor patients closely and withdraw approval if psychiatric risks outweigh cosmetic benefits.
Hold drug makers accountable for ongoing safety studies and full public disclosure.
Advice for Patients
Patients should weigh the psychiatric risks of finasteride before starting treatment. If experiencing mood changes, stop the drug and seek help. Alternatives exist and must be assessed for safety with a healthcare professional.
What are the long-term effects of finasteride on mental health?
Finasteride has been linked to increased risk of depression, anxiety, and suicidal ideation, with some users reporting persistent symptoms even after stopping the drug.
How have regulators responded to the warnings about finasteride?
What alternative treatments are available for hair loss?
How does finasteride affect brain chemistry?
What are the symptoms of post-finasteride syndrome?
Share this news:
